GlobeNewswire by notified

Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH

Share
  • Seven recruitments with solid track records and complementary profiles to reinforce Inventiva’s clinical expertise, medical team and corporate functions
  • New recruitments further expand the Company’s footprint in the United States while consolidating its presence in France

Daix (France), Long Island City (New York, United States), September 16, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced a series of recruitments with a view to accelerate the development of its lead drug candidate lanifibranor for the treatment of NASH.

The complementary profiles of the new arrivals will allow Inventiva to strengthen its expertise in clinical operations and drug development while reinforcing its core corporate functions.

Following the opening of Inventiva’s subsidiary in the United States in January 2021, these recruitments will further expand the Company’s footprint in this key geography and consolidate its presence in France.

Recruitments – Clinical operations and medical team

With over 20 years of experience in pharmaceutical and clinical development, Alice Roudot-Ketelers, PharmD, joins Inventiva as Vice President Clinical Operations and Pharmaceutical Development and member of its Executive Committee. Based in France, she will lead and oversee the Company’s global clinical and pharmaceutical development activities, particularly focusing on the development of lanifibranor and the recently launched pivotal NATiV3 Phase III clinical trial in NASH. Prior to joining Inventiva, Alice was in charge of all drug development programs and oversaw cross-functional teams in Chemistry, Manufacturing and Controls (CMC), non-clinical and clinical development up to Phase III at one of the major biotech companies in the NASH field.

Jean-Paul Dutertre, MD, joins the Company as Head of Pharmacovigilance in France, leading Inventiva’s pharmacovigilance activities with a focus on lanifibranor. Leveraging 30 years of experience in pharmacovigilance, Jean Paul worked for large pharmaceutical groups, including Eli Lilly and Company and GlaxoSmithKline, as well as biotech companies following his first position as Phase I physician at Fournier. In his different roles, Jean-Paul has led the establishment and maintenance of pharmacovigilance systems and processes. In this context, he frequently interacted with the U.S Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and was in charge, amongst others, of drafting the safety components for the applications of various drug candidates.

Sanjay Patel, MD, joins Inventiva in the role of Medical Director, with a proven expertise in diabetes and orphan diseases. Based in the United Kingdom, he reinforces Inventiva’s clinical team to support the development of lanifibranor for the treatment of NASH. Sanjay is an experienced Global Clinical Research Physician who has over 20 years of experience in clinical development within both large pharmaceutical groups, including Eli Lilly and Company, GlaxoSmithKline and Boehringer Ingelheim, and biotech companies.

Gerardo Rodriguez, MD, PhD, joins Inventiva as Senior Medical Director, based in the United States. With more than 17 years of experience in drug development, he will co-lead the Company’s pivotal Phase III clinical study with lanifibranor in NASH. Gerardo is a widely recognized cardiovascular endocrinologist, gene therapist and researcher, with a strong expertise across hepatology, diabetes, endocrinology and cardiovascular research, having worked for large pharmaceutical groups, biotech companies and Contract Research Organizations (CROs). Prior to joining Inventiva, Gerardo was the Head of Therapeutic Area of the Liver Disease Program at AbbVie, where he was involved in the Phase III clinical trial with cenicriviroc in NASH and led more than 45 Phase II clinical studies in NASH, in big and small pharmaceutical companies. Previously, Gerardo served as scientific advisor on NASH, diabetes and cardiovascular diseases for leading pharmaceutical companies, including Pfizer, Eli Lilly and Company, and Astra Zeneca.

Based in the United States, Joseph Covino, BS, joins the Company as Senior Director Clinical Operations to lead Inventiva’s clinical operations in the Unites States, with a primary focus on the Phase III clinical trial with lanifibranor. Joseph has more than 15 years of experience in drug development and managing clinical research trials, focusing on hepatology, cardiology, respiratory and rare diseases as well as oncology.

Recruitments – Corporate functions

Based in France, Eric Duranson, LLM, joins Inventiva in the role of General Counsel and as member of its Executive Committee. At Inventiva, he will focus on the acceleration of the Company’s strategy and further expansion. Eric has over 20 years of experience in the life sciences industry, supporting companies such as Thermo Fisher Scientific, Sanofi and bioMerieux, throughout all product development stages, from research and development to marketing.

PascalineClerc, PhD, joins the Company as Vice President Global External Affairs to lead Inventiva’s corporate and strategic communications, patient advocacy and stakeholder engagement to support the development of its pipeline, with a primary focus on lanifibranor and NASH. Based in the United States, Pascaline has more than 15 years of experience in patient engagement, particularly in the area of NASH as part of a Phase III clinical trial, public policy and scientific research.

Frédéric Cren, Chairman, CEO and cofounder of Inventiva, said: “We are delighted to welcome these important new hires. Reinforcing our presence in the U.S. and consolidating our footprint in France, they join us at a critical time, as we advance with the pivotal development of lanifibranor in NASH and the recently launched Phase III clinical trial. Their solid track records and complementary expertise, spanning clinical operations, drug development and corporate functions, will be a great addition to our teams and key to accelerate both the development of lanifibranor and our R&D portfolio at large.”

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of preclinical programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained FDA Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH. Lanifibranor is currently being evaluated in a pivotal Phase III clinical trial.

Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020.

In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).
www.inventivapharma.com

Contacts

Inventiva
Pascaline Clerc
VP of Global External Affairs
media@inventivapharma.com

+1 240 620 9175
Brunswick Group
Yannick Tetzlaff /
Tristan Roquet Montegon /
Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83
Westwicke, an ICR Company
Patricia L. Bank

Investor relations
Patti.bank@westwicke.com
+1 415 513 1284

Important Notice

This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva’s clinical trials, clinical trial data releases, clinical development plans and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, or that candidates will receive the necessary regulatory approvals. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2020 filed with the Autorité des Marchés Financiers on March 15, 2021, the Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 15, 2021 as well as the full-year financial report for the year ended December 31, 2020 for additional information in relation to such factors, risks and uncertainties.

Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Exterro Hires Rick Valentine as New Chief Customer Officer28.3.2024 14:00:00 CET | Press release

Seasoned executive will focus on ensuring Exterro customers maximize the value of their investment PORTLAND, Ore., March 28, 2024 (GLOBE NEWSWIRE) -- Exterro, the leading provider of data risk management software solutions, today announced the appointment of Rick Valentine, an expert in delivering world-class customer experiences at global organizations, as its new chief customer officer. The appointment reflects Exterro’s long-term commitment to delivering an outstanding experience and return on investment to all customers using its data risk management platform. Valentine will report directly to Exterro CEO Bobby Balachandran. Valentine brings more than three decades of leadership experience to the CCO position, most recently as chief customer officer at data management company Quantum. His prior executive experience encompasses both large public enterprises and high-growth startups in the high-tech space, including Silver Peak Systems/HPE, Veritas/Symantec, and Intuit. Valentine bri

Now Open for Nominations: The First Edition of the Stevie® Awards for Technology Excellence28.3.2024 14:00:00 CET | Press release

The newest edition of the world’s premier business awards will celebrate technology-related achievements worldwide FAIRFAX, Va., March 28, 2024 (GLOBE NEWSWIRE) -- The Stevie® Awards, organizers of the world’s premier business awards, have opened a ninth international competition: the Stevie® Awards for Technology Excellence. This new Stevie Awards program celebrates the remarkable accomplishments of individuals, teams, and organizations shaping the future of technology across all industry sectors. Individuals and organizations worldwide are eligible to enter – public and private, for-profit and non-profit, large and small. The program will recognize the world’s best technology professionals, organizations, achievements, products, and services since the beginning of 2022. The early-bird entry deadline, with reduced entry fees, is May 2. The entry deadline is May 30, but late entries will be accepted through June 28 with payment of a late fee. Entry details are available at www.StevieAw

HONKARAKENNE OYJ’S BOARD OF DIRECTORS DECIDED ON A SHARE-BASED INCENTIVE PROGRAM28.3.2024 14:00:00 CET | Press release

HONKARAKENNE OYJ Stock Exchange Release 28 March 2024 at 15:00 p.m. HONKARAKENNE OYJ’S BOARD OF DIRECTORS DECIDED ON A SHARE-BASED INCENTIVE PROGRAM As of 28.3.2024 The Board of Directors of Honkarakenne Oyj has decided on a share-based incentive program for 2024-2026. The purpose of the program is to engage key employees in the company’s objectives and create incentives for shareholder value growth. The performance share plan 2024-2026 consists of a 3-year performance period. Possible rewards will be paid in 2027, if the set performance targets are met. The performance metric applied to the performance period is company turnover and operating result %. The plan will involve a maximum of 9 individuals and the plan rewards will be equivalent to a maximum of 105,000 shares. HONKARAKENNE OYJ Board of Directors Additional information: CEO Marko Saarelainen, tel. +358 40 542 0254, marko.saarelainen@honka.com DISTRIBUTION Nasdaq Helsinki Ltd Key media Financial Supervisory Authority www.honk

Suominen extends the maturity of its revolving credit facility by one year28.3.2024 14:00:00 CET | Press release

Suominen Corporation’s press release on March 28, 2024 at 3:00p.m. (EET) Suominen signed in July 2020 a syndicated revolving credit facility agreement of EUR 100 million with maturity of three years with initially two one-year extension options, which both have been used. Suominen has now agreed on extending the maturity of the facility with additional year to July 2026. SUOMINEN CORPORATION For more information: Janne Silonsaari, CFO, tel. +358 50 409 9264 Suominen manufactures nonwovens as roll goods for wipes and other applications. Our vision is to be the frontrunner for nonwovens innovation and sustainability. The end products made of Suominen’s nonwovens are present in people’s daily life worldwide. Suominen’s net sales in 2023 were EUR 450.9 million and we have nearly 700 professionals working in Europe and in the Americas. Suominen’s shares are listed on Nasdaq Helsinki. Read more at www.suominen.fi.

AB Traction: Traction publicerar årsredovisningen och årsberättelsen för 202328.3.2024 13:30:00 CET | Pressemelding

AB Traction: Traction publicerar årsredovisningen och årsberättelsen för 2023 Tractions årsredovisning och årsberättelse för 2023 är nu offentliggjorda och finns tillgängliga på bolagets webbplats, www.traction.se Den tryckta versionen av årsberättelsen kan beställas genom e-post till post@traction.se. AB Traction Petter Stillström Verkställande direktör Tel: 08-506 289 00 DENNA INFORMATION ÄR SÅDAN INFORMATION SOM AB TRACTION ÄR SKYLDIGT ATT OFFENTLIGGÖRA ENLIGT LAGEN OM VÄRDEPAPPERSMARKNADEN. INFORMATIONEN LÄMNADES FÖR OFFENTLIGGÖRANDE DEN 28 MARS 2024, KL. 13.30 CET. Bilagor Traction Årsredovisning 2023traction-2023-12-31-svTraction Årsberättelse 2023

HiddenA line styled icon from Orion Icon Library.Eye